Facebook
Twitter
LinkedIn
Forward
A Multidisciplinary Approach for Addressing Challenges in Alzheimer's Disease
In a series of brief video segments, experts in neurology, psychiatry, and primary care discuss the diagnosis and treatment of Alzheimer’s disease.
Abstract
In this webcast, experts from the Banner health care system discuss the evaluation of cognitive concerns and cognitive impairment, and the diagnosis and management of Alzheimer’s disease (AD). Topics of the brief video clips include methods for developing therapeutic rapport with patients and their families, identifying and assessing the patient’s and/or the care partner’s concern, detecting cognitive impairment, characterizing the patient’s cognitive-behavioral syndrome, and investigating and determining the etiology of the cognitive impairment or dementia syndrome. The experts also address strategies for delivering a diagnosis to patients and their care partners, planning treatment regimens, and offering education and support. Task-sharing and collaboration must occur between specialists and primary care clinicians to address the growing number of individuals with AD and related dementias.
From the Series: A Multidisciplinary Approach for Addressing Challenges in Alzheimer's Disease
To cite: Atri A, Sheard S, Goldfarb D. A Multidisciplinary Approach for Addressing Challenges in Alzheimer's Disease. J Clin Psychiatry. 2021;82(00):MS18002WC4C
To share: https://doi.org/10.4088/JCP.MS18002WC4C
© Copyright 2019 Physicians Postgraduate Press, Inc.
Target Audience
Neurologists, psychiatrists, Primary Care Physicians (PCPs), Nurse Practitioners (NPs), and Physicians’ Assistants (PAs)
Learning Objectives
After completing this educational activity, you should be able to:
- Knowledgeably and compassionately disclose a dementia diagnosis to patients and their care partners
- Incorporate a process using observation, queries, and assessment tools for recognizing and diagnosing patients at risk for AD
- Provide pharmacologic and nonpharmacologic treatment options to diminish cognitive, behavioral, and psychological symptoms of AD, in conjunction with other health care providers
Support Statement
Supported by educational grants from ACADIA Pharmaceuticals Inc.; Allergan; Avanir Pharmaceuticals, Inc.; and Biogen MA, Inc.
Learning Objective
After completing this educational activity, you should be able to:
- Incorporate a process using observation, queries, and assessment tools for recognizing and diagnosing patients at risk for AD
- Knowledgeably and compassionately disclose a dementia diagnosis to patients and their care partners
- Provide pharmacologic and nonpharmacologic treatment options to diminish cognitive, behavioral, and psychological symptoms of AD, in conjunction with other health care providers
Release, Review, and Expiration Dates
This Webcast activity was published in August 2019 and is eligible for AMA PRA Category 1 Credit™ through August 31, 2022. The latest review of this material was July 2019.
Statement of Need and Purpose
Clinicians are missing the diagnosis of more than half of cases of Alzheimer’s disease (AD) and related dementias. When the illness is being recognized, providers often are not effectively communicating with patients and their care partners regarding the diagnosis and next steps. Clinicians also may not be optimally individualizing treatment options to best manage cognitive and behavioral symptoms in patients with AD. Task-sharing and collaboration must occur between specialists and primary care clinicians to address the growing number of individuals with AD and Related Dementias. Clinicians need education on early recognition of AD using a stepwise process that includes patient observation, informant report, use of assessment tools, and additional testing or referral, when appropriate. Practitioners also need guidance for sharing the diagnosis of AD along with education and next steps to take, including support services. Finally, providers need current information on pharmacologic and nonpharmacologic treatments for patients with AD. This activity was designed to meet the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc., who have requested information on AD.
Disclosure of Off-Label Usage
Dr Atri has determined that, to the best of his knowledge, no investigational information about pharmaceutical agents that is outside US Food and Drug Administration–approved labeling has been presented in this activity.
Review Process
The faculty members agreed to provide a balanced and evidence-based presentation and discussed the topics and CME objectives during the planning sessions. The faculty’s submitted content was validated by CME Institute staff, and the activity was evaluated for accuracy, use of evidence, and fair balance by the Chair and a peer reviewer who is without conflict of interest.
Acknowledgment
This activity is derived from the teleconference series “A Multidisciplinary Approach for Addressing Challenges in Alzheimer’s Disease,” which was held between September 2018 and April 2019 and is supported by educational grants from ACADIA Pharmaceuticals Inc.; Allergan; Avanir Pharmaceuticals, Inc.; and Biogen MA, Inc. The opinions expressed herein are those of the faculty and do not necessarily reflect the opinions of the CME provider and publisher or the commercial supporters.
Faculty Affiliation
Alireza Atri, MD, PhD
Banner Sun Health Research Institute, Sun City, Arizona
Simon Sheard, DO
Banner Health Center, Maricopa, Arizona
Danielle Goldfarb, MD
Banner Alzheimer’s Institute, Phoenix, Arizona
Financial Disclosure
The faculty for this CME activity and the CME Institute staff were asked to complete a statement regarding all relevant personal and financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. No member of the CME Institute staff reported any relevant personal financial relationships. Faculty financial disclosures are as follows:
The chair for this activity, Dr Atri, has no equity, shares, or salary from any pharmaceutical or biotechnology company and is not a member of any pharmaceutical company’s speakers’ bureau. In the last 12 months, Dr Atri has received honoraria for consulting, educational lectures/programs/materials, or medical/scientific advisory/data safety monitoring boards from AbbVie, Alzheimer’s Association, Eisai, Grifols, Harvard Medical School Graduate Continuing Education, Roche/Genentech, Suven, and Synexus. Dr Atri’s institution (Banner Health) has received observational study/clinical trial-related funding from Novartis and the Global Alzheimer’s Platform. Dr Atri has received book royalties from Oxford University Press. Drs Goldfarb and Sheard have no personal affiliations or financial relationships with any commercial interest to disclose relative to the activity.
Accreditation Statement
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
The CME Institute of Physicians Postgraduate Press, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hour of Category I credit for completing this program.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation